About MDI Bioscience
MDI Bioscience combines world-class expertise and non-mammalian disease models for target-based in vivo profiling of new drug compounds in whole organisms. Our assays deliver important data on the efficacy and organ toxicity of early-stage molecules before the initiation of costly and time-consuming mammalian studies. We use state-of-the-art gene-editing approaches like CRISPR to develop custom knock-in and knock-out models and transgenic biosensors in zebrafish, zebrafish larvae, and C. elegans. Assessing these models with high throughput imaging allows for faster screening of a greater number of compounds than would be possible with conventional mammalian models.
Learn MoreEarly-Stage In Vivo Profiling
Custom zebrafish, zebrafish embryos, and C. elegans basic research and lead discovery.
Simulated Biological Systems
Organoids and stem cell-based organ-on-a-chip technologies tailored to your target.
Advanced Bioinformatics
Statistical and multivariate analyses to deliver clear and actionable study data and analysis.
High Throughput Imaging
Rapid screening of large compound libraries and phenotypic drug development.